Discontinued — last reported Q1 '26
Merck & Co. Companion Animals — Sales decreased by 29.7% to $727.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 45.3%, from $1.33B to $727.00M. Over 4 years (FY 2021 to FY 2025), Companion Animals — Sales shows relatively stable performance with a 2.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests growing market share or higher demand for pet healthcare products, while a decrease may indicate increased competition or a slowdown in consumer spending on veterinary care.
This metric represents the total revenue generated from the sale of pharmaceutical products, vaccines, and health soluti...
Comparable to animal health revenue segments at companies like Zoetis or Elanco, typically benchmarked against overall pet care industry growth rates.
mrk_segment_companion_animal_sales| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.30B | $1.11B | $940.00M | $1.30B | $1.28B | $1.08B | $834.00M | $1.28B | $1.30B | $1.05B | $942.00M | $1.32B | $1.29B | $1.20B | $1.02B | $1.33B | $1.37B | $1.18B | $1.03B | $727.00M |
| QoQ Change | — | -15.1% | -15.0% | +38.3% | -1.4% | -15.4% | -23.1% | +54.0% | +1.1% | -19.0% | -10.5% | +40.4% | -2.5% | -6.9% | -15.3% | +30.6% | +3.2% | -13.6% | -12.7% | -29.7% |
| YoY Change | — | — | — | — | -1.5% | -2.0% | -11.3% | -1.2% | +1.2% | -3.0% | +12.9% | +3.0% | -0.6% | +14.2% | +8.0% | +0.4% | +6.2% | -1.4% | +1.7% | -45.3% |